Bioavailability Study of Gingerol and Ginger Extract Capsule in Healthy, Adult, Human Subjects under Fasting Conditions
*Corresponding Author:Received Date: Apr 03, 2024 / Published Date: Mar 17, 2025
Citation: Sheely JJ (2025) Bioavailability Study of Gingerol and Ginger Extract Capsule in Healthy, Adult, Human Subjects under Fasting Conditions. World J Pharmacol Toxicol 8: 297.
Copyright: © 2025 Sheely JJ. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
A comparative bioavailability study was conducted to assess gingerol and ginger extract capsule in healthy adult human subjects under fasting conditions. The study employed an open-label, balanced, randomized, single-dose, two-treatment, two-period, two-sequence, two-way crossover design. The genus Zingiber, encompassing ginger (Zingiber officinale Roscoe), was the focus due to its pharmacological properties, particularly its antiemetic effects attributed to its constituents, including gingerols. Thirty normal healthy adult male subjects were recruited, receiving oral doses of ginger extracts standardized to 5% gingerols, ranging from 100 mg to 2.0 g. Rapid absorption was observed with Tmax values ranging from 55 to 65.6 minutes and elimination half-lives ranging from 75 to 120 minutes at the highest dose. No serious adverse events were reported during active medication periods. The study indicated a statistically significant effect of gingerol in the initial treatment period, with no significant difference observed overall.
